Aileron Therapeutics: CMO Departs, New Interim CMO Appointed
Ticker: RNTX · Form: 8-K · Filed: May 16, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, officer-departure
TL;DR
Aileron Therapeutics' CMO is out, Dr. Allen steps in as interim CMO and joins the board.
AI Summary
Aileron Therapeutics, Inc. announced on May 15, 2024, the departure of Dr. Christopher P. Miller as Chief Medical Officer and the appointment of Dr. Andrew R. Allen as interim Chief Medical Officer. The company also elected Dr. Allen to its Board of Directors and announced a new compensatory arrangement for him.
Why It Matters
This filing indicates a leadership change in a key medical role, which could impact the company's strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like CMO, can signal internal shifts or challenges that may affect future performance.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Filer
- Dr. Christopher P. Miller (person) — Departing Chief Medical Officer
- Dr. Andrew R. Allen (person) — Appointed interim Chief Medical Officer and Director
- May 15, 2024 (date) — Date of Report
FAQ
Who has departed from Aileron Therapeutics, Inc.?
Dr. Christopher P. Miller has departed as Chief Medical Officer.
Who has been appointed as the interim Chief Medical Officer?
Dr. Andrew R. Allen has been appointed as the interim Chief Medical Officer.
What other role has Dr. Andrew R. Allen taken on?
Dr. Andrew R. Allen has also been elected to the Board of Directors.
What is the effective date of these changes?
The earliest event reported is dated May 15, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-05-16 17:01:16
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d841479d8k.htm (8-K) — 24KB
- 0001193125-24-140688.txt ( ) — 147KB
- alrn-20240515.xsd (EX-101.SCH) — 3KB
- alrn-20240515_lab.xml (EX-101.LAB) — 18KB
- alrn-20240515_pre.xml (EX-101.PRE) — 11KB
- d841479d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aileron Therapeutics, Inc. Date: May 16, 2024 By: /s/ Brian Windsor Brian Windsor, Ph.D. President and Chief Executive Officer